Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2010

Open Access 01-12-2010 | Research

Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades

Authors: Mei-Jen Wang, Hsin-Yi Huang, Wu-Fu Chen, Hui-Fen Chang, Jon-Son Kuo

Published in: Journal of Neuroinflammation | Issue 1/2010

Login to get access

Abstract

Background

Deciphering the mechanisms that modulate the inflammatory response induced by microglial activation not only improves our insight into neuroinflammation but also provides avenues for designing novel therapies that could halt inflammation-induced neuronal degeneration. Decreasing glycogen synthase kinase-3β (GSK-3β) activity has therapeutic benefits in inflammatory diseases. However, the exact molecular mechanisms underlying GSK-3β inactivation-mediated suppression of the inflammatory response induced by microglial activation have not been completely clarified. Tumor necrosis factor-α (TNF-α) plays a central role in injury caused by neuroinflammation. We investigated the regulatory effect of GSK-3β on TNF-α production by microglia to discern the molecular mechanisms of this modulation.

Methods

Lipopolysaccharide (LPS) was used to induce an inflammatory response in cultured primary microglia or murine BV-2 microglial cells. Release of TNF-α was measured by ELISA. Signaling molecules were analyzed by western blotting, and activation of NF-κB and AP-1 was measured by ELISA-based DNA binding analysis and luciferase reporter assay. Protein interaction was examined by coimmunoprecipitation.

Results

Inhibition of GSK-3β by selective GSK-3β inhibitors or by RNA interference attenuated LPS-induced TNF-α production in cultured microglia. Exploration of the mechanisms by which GSK-3β positively regulates inflammatory response showed that LPS-induced IκB-α degradation, NF-κBp65 nuclear translocation, and p65 DNA binding activity were not affected by inhibition of GSK-3β activity. However, GSK-3β inactivation inhibited transactivation activity of p65 by deacetylating p65 at lysine 310. Furthermore, we also demonstrated a functional interaction between mixed lineage kinase 3 (MLK3) and GSK-3β during LPS-induced TNF-α production in microglia. The phosphorylated levels of MLK3, MKK4, and JNK were increased upon LPS treatment. Decreasing GSK-3β activity blocked MLK3 signaling cascades through disruption of MLK3 dimerization-induced autophosphorylation, ultimately leading to a decrease in TNF-α secretion.

Conclusion

These results suggest that inactivation of GSK-3β might represent a potential strategy to downregulate microglia-mediated inflammatory processes.
Appendix
Available only for authorised users
Literature
1.
Mrak RE, Griffin WS: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005, 26: 349-354. 10.1016/j.neurobiolaging.2004.05.010.CrossRefPubMed
2.
Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med. 2006, 12: 1005-1015.PubMed
3.
McGeer PL, McGeer EG: Glial reactions in Parkinson's disease. Mov Disord. 2008, 23: 474-483. 10.1002/mds.21751.CrossRefPubMed
4.
Grimes CA, Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001, 65: 391-426. 10.1016/S0301-0082(01)00011-9.CrossRefPubMed
5.
Jiang H, Guo W, Liang X, Rao Y: Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3β and its upstream regulators. Cell. 2005, 120: 123-135.PubMed
6.
Sanchez JF, Sniderhan LF, Williamson AL, Fan S, Chakraborty-Sett S, Maggirwar SB: Glycogen synthase kinase 3β-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor κB signaling. Mol Cell Biol. 2003, 23: 4649-4662. 10.1128/MCB.23.13.4649-4662.2003.PubMedCentralCrossRefPubMed
7.
Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K, Kracht M: Phosphorylation of serine 468 by GSK-3β negatively regulates basal p65 NF-κB activity. J Biol Chem. 2004, 279: 49571-49574. 10.1074/jbc.C400442200.CrossRefPubMed
8.
Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB: Genetic deletion of glycogen synthase kinase-3β abrogates activation of IκBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem. 2004, 279: 39541-39554. 10.1074/jbc.M403449200.CrossRefPubMed
9.
Shen E, Fan J, Peng T: Glycogen synthase kinase-3beta suppresses tumor necrosis factor-alpha expression in cardiomyocytes during lipopolysaccharide stimulation. J Cell Biochem. 2008, 104: 329-338. 10.1002/jcb.21629.CrossRefPubMed
10.
Vines A, Cahoon S, Goldberg I, Saxena U, Pillarisetti S: Novel inflammatory role for glycogen synthase-3β in the inhibition of TNF-α and IL-1β induced inflammatory gene expression. J Biol Chem. 2006, 281: 16985-16990. 10.1074/jbc.M602446200.CrossRefPubMed
11.
Martin M, Rehani K, Jope RS, Michalek SM: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 2005, 6: 777-784. 10.1038/ni1221.PubMedCentralCrossRefPubMed
12.
Huang WC, Lin YS, Wang CY, Tsai CC, Tseng HC, Chen CL, Lu PJ, Chen PS, Qian L, Hong JS, Lin CF: Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology. 2009, 128: e275-286. 10.1111/j.1365-2567.2008.02959.x.PubMedCentralCrossRefPubMed
13.
Yuskaitis CJ, Jope RS: Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal. 2009, 21: 264-273. 10.1016/j.cellsig.2008.10.014.PubMedCentralCrossRefPubMed
14.
Colasanti M, Persichini T, Pucchio TDi, Gremo F, Lauro GM: Human ramified microglial cells produce nitric oxide upon Escherichia coli lipopolysaccharide and tumor necrosis factor alpha stimulation. Neurosci Lett. 1995, 200: 144-146. 10.1016/0304-3940(95)12101-9.CrossRefPubMed
15.
Marcus JS, Karackattu SL, Fleegal MA, Sumners C: Cytokine-stimulated inducible nitric oxide synthase expression in astroglia: role of Erk mitogen-activated protein kinase and NF-kappaB. Glia. 2003, 41: 152-160. 10.1002/glia.10168.CrossRefPubMed
16.
Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W: Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. J Biol Chem. 1992, 267: 5317-5323.PubMed
17.
Goossens V, Grooten J, De Vos K, Fiers W: Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA. 1995, 92: 8115-8119. 10.1073/pnas.92.18.8115.PubMedCentralCrossRefPubMed
18.
Hsu H, Xiong J, Goeddel DV: The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 1995, 81: 495-504. 10.1016/0092-8674(95)90070-5.CrossRefPubMed
19.
Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, Wolf-Klein G: Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett. 1991, 129: 318-320. 10.1016/0304-3940(91)90490-K.CrossRefPubMed
20.
Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T: Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994, 165: 208-210. 10.1016/0304-3940(94)90746-3.CrossRefPubMed
21.
Raine CS: Multiple sclerosis: immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol. 1994, 53: 328-337. 10.1097/00005072-199407000-00002.CrossRefPubMed
22.
Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, Bachetti T: Circulating levels of tumor necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett. 2000, 287: 211-214. 10.1016/S0304-3940(00)01177-0.CrossRefPubMed
23.
Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP: Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implication for Parkinson's disease. FASEB J. 2002, 16: 1474-1476.PubMed
24.
McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG: Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci. 2006, 26: 9365-9375. 10.1523/JNEUROSCI.1504-06.2006.PubMedCentralCrossRefPubMed
25.
Meda L, Cassatella MA, Szendrei GI, Otvos L, Baron P, Villalba M, Ferrari D, Rossi F: Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995, 374: 647-650. 10.1038/374647a0.CrossRefPubMed
26.
Lio D, Annoni G, Licastro F, Crivello A, Forte GI, Scola L, Colonna-Romano G, Arosio B, Galimberti L, Vergani C, Caruso C: Tumor necrosis factor-alpha -308A/G polymorphism is associated with age at onset of Alzheimer's disease. Mech Ageing Dev. 2006, 127: 567-571. 10.1016/j.mad.2006.01.015.CrossRefPubMed
27.
McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG: Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009, 34: 163-177. 10.1016/j.nbd.2009.01.006.PubMedCentralCrossRefPubMed
28.
Tobinick EL, Gross H: Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation. 2008, 5: 2-11. 10.1186/1742-2094-5-2.PubMedCentralCrossRefPubMed
29.
West M, Mhatre M, Ceballos A, Floyd RA, Grammas P, Gabbita PS, Hamdheydari L, Mai T, Mou S, Pye QN, Stewart C, west S, Williamson KS, Zemlan F, Hensley K: The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem. 2004, 91: 133-143. 10.1111/j.1471-4159.2004.02700.x.CrossRefPubMed
30.
Wang M-J, Lin S-Z, Kuo J-S, Huang H-Y, Tzeng S-F, Liao C-H, Chen D-C, Chen W-F: Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J Immunol. 2007, 179: 6204-6214.CrossRefPubMed
31.
Ding S, Wu TYH, Brinker A, Peters EC, Hur W, Gray NS, Schultz PG: Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci USA. 2003, 100: 7632-7637. 10.1073/pnas.0732087100.PubMedCentralCrossRefPubMed
32.
Covert MW, Leung TH, Gaston JE, Baltimore D: Achieving stability of lipopolysaccharide-induced NF-κB activation. Science. 2005, 309: 1854-1857. 10.1126/science.1112304.CrossRefPubMed
33.
Werner SL, Barken D, Hoffmann A: Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science. 2005, 309: 1857-1861. 10.1126/science.1113319.CrossRefPubMed
34.
Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G: Transcriptional activation of the NF-kB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J. 2003, 22: 1313-1324. 10.1093/emboj/cdg139.PubMedCentralCrossRefPubMed
35.
Yang F, Tang E, Guan K, Wang C-Y: IKKβ plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol. 2003, 170: 5630-5635.CrossRefPubMed
36.
Chen L-F, Fischle W, Verdin E, Greene WC: Duration of nuclear NF-κB action regulated by reversible acetylation. Science. 2001, 293: 1653-1657. 10.1126/science.1062374.CrossRef
37.
Chen L-F, Mu Y, Greene WC: Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 2002, 21: 6539-6548. 10.1093/emboj/cdf660.PubMedCentralCrossRefPubMed
38.
Bhat NR, Zhang P, Lee JC, Hogan EL: Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinase regulate inducible nitric oxide synthase and tumor necrosis factor-α gene expression in endotoxin-stimulated primary glial cultures. J Neurosci. 1998, 18: 1633-1641.PubMed
39.
Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M: Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature. 1991, 354: 494-496. 10.1038/354494a0.CrossRefPubMed
40.
Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell. 2000, 103: 239-252. 10.1016/S0092-8674(00)00116-1.CrossRefPubMed
41.
Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ: MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev. 2001, 15: 1419-1426. 10.1101/gad.888501.PubMedCentralCrossRefPubMed
42.
Wang X, Destrument A, Tournier C: Physiological roles of MKK4 and MKK7: insights from animal models. Biochim Biophys acta. 2007, 1773: 1349-1357. 10.1016/j.bbamcr.2006.10.016.CrossRefPubMed
43.
Xu Z, Maroney AC, Dobrzanski P, Kukekov NV, Greene LA: The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol. 2001, 21: 4713-4724. 10.1128/MCB.21.14.4713-4724.2001.PubMedCentralCrossRefPubMed
44.
Gallo KA, Johnson GL: Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol. 2002, 3: 663-672. 10.1038/nrm906.CrossRefPubMed
45.
Leung IW, Lassam N: The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoietic progenitor kinase 1 phosphorylation. J Biol Chem. 2001, 276: 1961-1967. 10.1074/jbc.M004092200.CrossRefPubMed
46.
Roux PP, Dorval G, Boudreau M, Angers-Loustau A, Morris SJ, Makkerh J, Barker PA: K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J Biol Chem. 2002, 277: 49473-49480. 10.1074/jbc.M203428200.CrossRefPubMed
47.
Pan J, Zhang Q-G, Zhang G-Y: The neuroprotective effects of K252a through inhibiting MLK3/MKK7/JNK3 signaling pathway on ischemic brain injury in rat hippocampal CA1 region. Neuroscience. 2005, 131: 147-159. 10.1016/j.neuroscience.2004.09.031.CrossRefPubMed
48.
Mishra R, Barthwal MK, Sondarva G, Rana B, Wong L, Chatterjee M, Woodgett JR, Rana A: Glycogen synthase kinase-3β induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. J Biol Chem. 2007, 282: 30393-30405. 10.1074/jbc.M705895200.CrossRefPubMed
49.
Leung IW, Lassam N: Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3. J Biol Chem. 1998, 273: 32408-32415. 10.1074/jbc.273.49.32408.CrossRefPubMed
50.
Jope RS, Yuskaitis CJ, Beurel E: Glycogen synthase kinase-3 (GSK3) : inflammation, diseases, and therapeutics. Neurochem Res. 2007, 32: 577-595. 10.1007/s11064-006-9128-5.PubMedCentralCrossRefPubMed
51.
Guha M, Mackman N: The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002, 277: 32124-32132. 10.1074/jbc.M203298200.CrossRefPubMed
52.
Hoeflich KP, Luo J, Rubie EA, Tsao M-S, Jin O, Woodgett JR: Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature. 2000, 406: 86-90. 10.1038/35017574.CrossRefPubMed
53.
54.
Haefner B: A model for NF-kappa B regulation by GSK-3 beta. Drug Discov Today. 2003, 8: 1062-1063. 10.1016/S1359-6446(03)02898-8.CrossRefPubMed
55.
Steinbrecher KA, Wilson W, Cogswell PC, Baldwin AS: Glycogen synthase kinase 3β functions to specify gene-specific, NF-κB-dependent transcription. Mol Cell Biol. 2005, 25: 8444-8455. 10.1128/MCB.25.19.8444-8455.2005.PubMedCentralCrossRefPubMed
56.
Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G: Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol. 2002, 64: 963-970. 10.1016/S0006-2952(02)01161-9.CrossRefPubMed
57.
58.
Schmitz ML, Mattioli I, Buss H, Kracht M: NF-kappaB: a multifaceted transcription factor regulated at several levels. Chembiochem. 2004, 5: 1348-1358. 10.1002/cbic.200400144.CrossRefPubMed
59.
Gong R, Rifai A, Ge Y, Chen S, Dworkin LD: Hepatocyte growth factor suppresses proinflammatory NFκB activation through GSK3β inactivation in renal tubular epithelial cells. J Biol Chem. 2008, 283: 7401-7410. 10.1074/jbc.M710396200.PubMedCentralCrossRefPubMed
60.
Chen L-F, Greene WC: Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol. 2004, 5: 392-401. 10.1038/nrm1368.CrossRefPubMed
61.
Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S, Benkirane M: Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem. 2003, 278: 2758-2766. 10.1074/jbc.M209572200.CrossRefPubMed
62.
63.
Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S, Goetz M, Lucius R, Herdegen T, Hanisch UK: c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia. 2005, 50: 235-246. 10.1002/glia.20173.CrossRefPubMed
64.
Liu S, Yu S, Hasegawa Y, LaPushin R, Xu H-J, Woodgett JR, Mills GB, Fang X: Glycogen synthase kinase 3β is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem. 2004, 279: 51075-51081. 10.1074/jbc.M408607200.CrossRefPubMed
65.
Kim JW, Lee JE, Kim MJ, Cho E-G, Cho S-G: Glycogen synthase kinase 3β is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem. 2003, 278: 13995-14001. 10.1074/jbc.M300253200.CrossRefPubMed
66.
Jope RS, Yuskaitis CJ, Beurel E: Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007, 32: 577-595. 10.1007/s11064-006-9128-5.PubMedCentralCrossRefPubMed
Metadata
Title
Glycogen synthase kinase-3β inactivation inhibits tumor necrosis factor-α production in microglia by modulating nuclear factor κB and MLK3/JNK signaling cascades
Authors
Mei-Jen Wang
Hsin-Yi Huang
Wu-Fu Chen
Hui-Fen Chang
Jon-Son Kuo
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2010
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-7-99

Other articles of this Issue 1/2010

Journal of Neuroinflammation 1/2010 Go to the issue

Research

A neurotoxic regimen of methamphetamine exacerbates the febrile and neuroinflammatory response to a subsequent peripheral immune stimulus

Research

Central Administration of Lipopolysaccharide Induces Depressive-like Behavior in Vivo and Activates Brain Indoleamine 2,3 Dioxygenase In Murine Organotypic Hippocampal Slice Cultures

Research

Chronic immobilisation stress ameliorates clinical score and neuroinflammation in a MOG-induced EAE in Dark Agouti rats: mechanisms implicated

Short report

Neurotensin is increased in serum of young children with autistic disorder

Case study

IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients

Research

Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease